



- (51) **International Patent Classification:**
Not classified
- (21) **International Application Number:**
PCT/SG2023/050007
- (22) **International Filing Date:**
04 January 2023 (04.01.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/266,477 06 January 2022 (06.01.2022) US
- (71) **Applicants:** **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **NANYANG TECHNOLOGICAL UNIVERSITY** [SG/SG]; 50 Nanyang Avenue, Singapore 639798 (SG).
- (72) **Inventors:** **CHAN, Bee Eng, Mary**; c/o Nanyang Technological University, School of Chemical and Biomedical Engineering, 62 Nanyang Drive, Singapore 637459 (SG). **HAMMOND CUNNINGHAM, Paula**; c/o Massachusetts Institute of Technology, David H Koch Institute For Integrative Cancer Research, 500 Main Street, 76-553, Cam-


bridge, Massachusetts 02139-4307 (US). **ZHANG, Kaixi**; c/o Nanyang Technological University, School of Chemical and Biomedical Engineering, 62 Nanyang Drive, Singapore 637459 (SG). **FERGUSON, Michelle, Elizabeth**; c/o Singapore-MIT Alliance For Research and Technology, 1 Create Way, #03-13/14 Enterprise Wing, Singapore 138602 (SG).

- (74) **Agent:** **DOWSING, Bruce John**; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P O Box 636, Singapore 910816 (SG).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (54) **Title:** POLYIMIDAZOLIUM-BASED CATIONIC ANTIMICROBIAL POLYMERS FOR NOVEL MASTITIS PROPHYLACTIC SOLUTIONS

Figure 2
A



- (57) **Abstract:** The present invention relates to a composition comprising a polyimidazolium (PIM) compound for use in the treatment and/or prevention of mastitis in a mammal, and to methods of use.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*